Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study

International Journal of Cancer

Volumn 76, Issue 3, 1998, Pages 325-330

  Mignotte, Hervé ^a   Lasset, Christine ^a   Bonadona, Valérie ^a   Lesur, Anne ^b   Luporsi, Elisabeth ^b   Roodier, Jean François ^c   Cutuli, Bruno ^c   Lasry, Serge ^d   Mauriac, Louis ^e   Granon, Claire ^f   Kerr, Christine ^g   Giard, Sylvie ^h   Hill, Catherine ⁱ   De Lafontan, Brigitte ^j   De Gislain, Catherine ^k   Anjou, Joëlle D' ^l   Fondrinier, Eric ^m   Lefeuvre, Claudia ⁿ   Parache, Robert Michel ^b   Chauvin, Franck ^a  

^a CENTRE LÉON BÉRARD   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c CENTRE PAUL STRAUSS   (France)

^d CENTRE RENÉ HUGUENIN   (France)

^e INSTITUT BERGONIÉ   (France)

^f CENTRE ANTOINE LACASSAGNE   (France)

^g CENTRE VAL D AURELLE   (France)

^h CENTRE OSCAR LAMBRET   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j INSTITUT CLAUDIUS REGAUD   (France)

^k Georges Franois Leclerc Cancer Center   (France)

^l CENTRE HENRI BECQUEREL   (France)

^m CENTRE PAUL PAPIN   (France)

ⁿ CENTRE EUGÈNE MARQUIS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FRANCE; HUMAN; IATROGENIC DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; FRANCE; HUMANS; MIDDLE AGED; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 18144451781     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980504)76:3<325::AID-IJC7>3.0.CO;2-X     Document Type: Article

References (21)

1. ASSIKIS, V.J., NEVEN, P., JORDAN, V.C. and VERGOTE, I., A realistic perspective of tamoxifen and endometrial carcinogenesis. Europ. J. Cancer, 32A, 1464-1476 (1996).
2. BARAKAT, R.R., WONG. G., CURTIN. J.P., VLAMIS, V. and HOSKINS, W.J., Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologie features. Gynecoi Oncol., 55, 164-168 (1994).
3. BRESLOW, N.E. and DAY, N.E., Statistical methods in cancer research. Vol. I. The analysis of case-control studies, International Agency for Research on Cancer, Lyon (1980).
4. COOK, L.S., WEISS, N.S., SCHWARTZ, S.M., WHITE, E., MCKNIGHT, B., MOORE, D.E. and DAUNG, J.R., Population-based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancers. J. nat. Cancer Inst., 18, 1359-1364 (1995).
5. COURT, C., International group evaluates tamoxifen risks in women. Brit. Med. J., 312, 529 (1996).
6. EARLY BREAST CANCER TRIALIST'S COLLABORATIVE GROUP, Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet, 339, 7-15, 71-85 (1992).
7. FISHER, B., COSTANTTNO, J.P., REDMOND, C.K., FISCHER, E.R., WICKERHAM, D.L., CRONIN, V.M. and OTHER NSABP CONTRIBUTORS, Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. nat. Cancer Inst., 86, 527-537 (1994).
8. FORNANDER, T., HELLSTRÖM, A.C., and MOBERGER, B., Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after tamoxifen in early breast cancer. J. nat. Cancer Inst., 85, 1850-1855 (1993).
9. FORNANDER, T., RUTQVIST, L.E., CEDERMARK. B., GLAS, U., MATTSSON, A., SILFVERSWARD, C., LAMBERT. S., SOMELL, A., THEVE, T., WlLHING, N., ASKERGREN, J. and AJALMAR, M.L., Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, 1, 117-120 (1989).
10. HARDELL, L., Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. Lancet, i, 1432 (1988).
11. MAGRIPLES, U., NAFTOUN, F. SCHWARTZ, P.E. and CARCANGIU, M.L., Hish-srade endometrial carcinoma in tamoxifen treated breast cancer patients. J. din. Oncol., 11,485-490 (1993).
12. MHREDITH, R.F., EISERT, D.R., KAKA, Z., HOIDISON, E., JOHNSTON, G.A. and BOUTSELIS, J.G., An excess of uterine sarcomas after pelvic irradiation. Cancer. 58, 2003-2007 (1986).
13. N.A.T.O. (NOLVADEX ADJUVANT TRIAL ORGANISATION), Controlled triai of tamoxiten as a single adjuvant agent in management of early breast cancer. Analysis at eight years by the Nolvadex Adjuvant Trial Organisation. Brit. J. Cancer, 57, 608-611 (1988).
14. NAYFIELD, S.G., KARP, J.E., FORD, L.G., DORR, F.A. and KRAMER, B.S., Potential role of tamoxiten in prevention of breast cancer. J. nat. Cancer Inst., 83, 1450-1459 (1991).
15. OLAH, K.S., GEE, H., BLUNT, S., DUNN, J.A., KELLY, K. and CHAN, K.K., Retrospective analysis of 318 cases of uterine sarcoma. Eur. J. Cancer, 27, 1095-1099 (1991).
16. RIBEIRO, G. and SWINDELL, R., The Christie Hospital adjuvant tamoxiten trial. Status at 10 years. Brit. J. Cancer, 57, 601-603 (1988).
17. RUTQVIST, L.E., JOHANSSON, H., SlGNOMKLAO, T., JOHANSSON, U., FORNANDER, T. and WILKING, N., FOR THE STOCKHOLM BREAST CANCER STUDY GROUP. Adjuvant tamoxifen therapy for early breast cancer and second primary malignancies. J. nat. Cancer Inst., 9, 645-650 (1995).
18. SASCO, A.J., CHAPLAIN, G., AMOROS, E. and SAEZ, S., Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology, 7, 9-13 (1996).
19. SCOTTISH CANCER TRIAL OFFICE, Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet, ii, 171-175 (1987).
20. SILVA, E.G., TORNOS, C.S. and POLLEN, MITCHELL, M., Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effect of tamoxifen. Int. J. Gynecol. Pathol., 13, 248-258 (1994).
21. VAN LEEUWEN, F.E., BENRAADT, J., COEBERGH, J.W., KIEMENEY, L.A.L.M., GIMBRERE, C.H.F., OTTER, R., SHOUTEN, L.J., DAMHUIS, R.A.M., BONTENBAL, M., DIEPENHORST, F.W., VAN DEN BELT-DUSEBOUT, A.W. and VAN TINTEREN, H., Risk of endometrial cancer after tamoxifen treatment for breast cancer. Lancet, 343, 448-452 (1994). \